BUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan

Reuters11-13

** Shares of drug-developer Tharimmune THAR.O rise 1.58% to $3.24 premarket

** Co says it receives positive feedback from the U.S. FDA for its experimental drug TH104, designed to prevent breathing problems caused by fentanyl and other powerful opioids

** The FDA agrees with co's plan to use computer modeling to show how the drug works in the body and offers technical advice to improve the study - THAR

** Co's TH104 is a thin film that dissolves in the mouth, designed for easy use by first responders or military personnel exposed to dangerous opioids - THAR

** Co simulations show TH104 starts working in 30 min and protects for 24 hrs vs naloxone's <2 hrs

** Up to last close, stock up ~59% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583459369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583459369","market":"us","top_or_hot":-1,"title":"BUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan</title></head><body><p>** Shares of drug-developer Tharimmune <span>THAR.O</span> rise 1.58% to $3.24 premarket</p><p>** Co says it receives positive feedback from the U.S. FDA for its experimental drug TH104, designed to prevent breathing problems caused by fentanyl and other powerful opioids</p><p>** The FDA agrees with co's plan to use computer modeling to show how the drug works in the body and offers technical advice to improve the study - THAR</p><p>** Co's TH104 is a thin film that dissolves in the mouth, designed for easy use by first responders or military personnel exposed to dangerous opioids - THAR</p><p>** Co simulations show TH104 starts working in 30 min and protects for 24 hrs vs naloxone's &lt;2 hrs</p><p>** Up to last close, stock up ~59% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan</title></head><body><p>** Shares of drug-developer Tharimmune <span>THAR.O</span> rise 1.58% to $3.24 premarket</p><p>** Co says it receives positive feedback from the U.S. FDA for its experimental drug TH104, designed to prevent breathing problems caused by fentanyl and other powerful opioids</p><p>** The FDA agrees with co's plan to use computer modeling to show how the drug works in the body and offers technical advice to improve the study - THAR</p><p>** Co's TH104 is a thin film that dissolves in the mouth, designed for easy use by first responders or military personnel exposed to dangerous opioids - THAR</p><p>** Co simulations show TH104 starts working in 30 min and protects for 24 hrs vs naloxone's &lt;2 hrs</p><p>** Up to last close, stock up ~59% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4N3WP0ZB:1","article_id":"2583459369","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583459369","pubTimestamp":1763041093,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan** Shares of drug-developer Tharimmune THAR.O rise 1.58% to $3.24 premarket** Co says it receives positive feedback from the U.S. FDA for its experimental drug TH104, designed to prevent breathing problems caused by fentanyl and other powerful opioids** The FDA agrees with co's plan to use computer modeling to show how the drug works in the body and offers technical advice to improve the study - THAR** Co's TH104 is a thin film that dissolves in the mouth, designed for easy use by first responders or military personnel exposed to dangerous opioids - THAR** Co simulations show TH104 starts working in 30 min and protects for 24 hrs vs naloxone's <2 hrs** Up to last close, stock up ~59% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","THAR":"Tharimmune Inc."},"translate_title":"美国FDA支持阿片类药物过量预防药物计划后，BUZZ-Tharimmune股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THAR":0.9},"content_text":"BUZZ-Tharimmune rises after US FDA backs opioid overdose prevention drug plan** Shares of drug-developer Tharimmune THAR.O rise 1.58% to $3.24 premarket** Co says it receives positive feedback from the U.S. FDA for its experimental drug TH104, designed to prevent breathing problems caused by fentanyl and other powerful opioids** The FDA agrees with co's plan to use computer modeling to show how the drug works in the body and offers technical advice to improve the study - THAR** Co's TH104 is a thin film that dissolves in the mouth, designed for easy use by first responders or military personnel exposed to dangerous opioids - THAR** Co simulations show TH104 starts working in 30 min and protects for 24 hrs vs naloxone's <2 hrs** Up to last close, stock up ~59% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583459369","isCrawlerRequest":true}